Kornimate/medical-research-clean huggingface dataset:
effect of high velocity/hyperoxic breathing therapy on blood lactate decline

Conditions: Dyspnea; Lactic Acidosis; Muscle; Breathlessness; Exercise; Recovery

Summary: the study will evaluate the impact of high velocity therapy (hvt) on reduction of work of breathing (as implied by breath frequency) and enhanced blood lactate decline during recovery from a wingate-type exercise test. the study will include four study segments, corresponding to four different therapy settings.

hvt has been found to be a useful clinical tool for treatment of type 1 and type 2 respiratory failure (including hypercapnic respiratory failure), acute decompensated heart failure, and covid respiratory complications. the overall objective of this prospective, pilot study is to evaluate whether hvt might enhance the decline of blood lactate concentrations following a high intensity exercise bout, in healthy volunteers. the hypothesis is that hvt, regardless of the oxygen concentration (i.e., fio2), will reduce the work of breathing and increase the lactate clearance rate during exercise and recovery intervals. this pilot study could ignite further research providing hvt applications to high performing athletics and patients in an acute care setting requiring physical rehabilitation.

Eligibility criteria:
inclusion criteria: * adults18-30 years old, in a general state of good health, of either sex * no known contraindication to performing a maximal exercise test, i.e., wingate-type anaerobic exercise test * participants must consider themselves able to perform "regular moderate" or "regular strenuous" exercise. * ° "regular moderate" exercise includes less than 30 minutes every day or 30 minutes every other day, of some form of deliberate exercise, that does not include walking. * ° "regular strenuous" exercise is 30+ minutes per day, of some form of deliberate exercise, that does not include walking. exclusion criteria: * not considered a 'high-performance athlete' * known active cardiovascular, metabolic, liver, or renal disease * orthopedic limitations to exercise * pregnancy * use of beta-blockers or beta-agonist asthma medications * exercise induced asthma * any other health-related issue that would involve the participant's fitness capability * inability to complete all of the study procedures
the qingdao port health study

Conditions: Chronic Disease

Summary: china, efforts are underway to respond to an unprecedented epidemiologic transition, with soaring rates of cardiovascular disease (cvd), including heart disease and stroke. yet there may be limitations in translating observations and findings derived from anglo-based population studies. as such, there is a critical need for population-based studies that provide insight into the risk factors, incidence, and outcomes of cvd in china. the qingdao port health study is a population-based prospective cohort study of employees of the qingdao port group, china, designed to investigate the burden of cvd and risk factors (e.g., sociodemographic, biological, environmental and clinical factors) associated with disease onset and outcomes.

in qingdao port, annual health assessments are offered at 3 on-site health clinics. the annual health assessment consists of a questionnaire, physical examination, laboratory tests, bio-sampling, and imaging examinations.in each year, demographics information, medical history, medication use and adherence, family history,lifestyles (e.g., nutritional intake; physical activity; smoking; alcohol use/abuse), menopause (including hormone use) and quality of life were collected by trained researchers.in 2013, blood and saliva samples were collected. follow-up health assessments are performed every year. the outcomes of cardiovascular disease (angina, myocardial infarction, heart failure, stroke, revascularization), non-communicable diseases (chronic obstructive pulmonary disease, renal failure, liver disease and cancer), and all-cause death are collected from local medical insurance database.this study aim to surveillance of cardiovascular and other non-communicable diseases (risk factors, health outcomes and trends) and investigate of socio-cultural, biological, behavioral, social, and environmental factors on work performance, cardiovascular disease onset and cardiovascular health outcomes.

Eligibility criteria:
inclusion criteria: * all employees and retirees in qingdao port group * aged over 18 years old exclusion criteria: -

Keywords: chronic diseases risk factors health outcomes
the environment's impact on thinking when added to leg cycling in people with tbi: vital

Conditions: Traumatic Brain Injury

Summary: aerobic exercise is a promising treatment modality for cognition in persons with tbi, but effects are consistently small. this study aims to investigate the effect of difference environments during moderate intensity cycling sessions on cognition.

the proposed research study would be the first to investigate the acute effects of aerobic exercise with different environments relative to control and comparison conditions on several domains of cognition in people with tbi. this critical investigation will be a first step toward systematically identifying an optimal exercise training intervention for managing common cognitive consequences of tbi.

Eligibility criteria:
inclusion criteria: * be at least 18 years of age and younger than 59 years of age * speak english as their primary language * have had a previous tbi at least one year prior\\ exclusion criteria: * have contraindications to moderate or high intensity physical activity, based on the physical activity readiness questionnaire (par-q) * have a history of psychiatric illness (ex: major depression, bipolar disorder, schizophrenia), neurological disorders beyond tbi (ex: stroke, seizure disorder), or substance abuse * currently use medications that might impact cognition (ex: steroids, benzodiazepines, neuroleptics) * be currently pregnant * have visual impairments not otherwise corrected by contact lenses (ex: stereo blindness, colorblindness) * have a high likelihood of motion sickness

Keywords: brain injuries, traumatic aerobic exercise leg cycling virtual reality
efficacy and safety of viusid in patients with hepatic cirrhosis secondary to hepatitis c virus infection.

Conditions: Cirrhosis; Chronic Hepatitis C

Summary: the purpose of the study is to evaluate whether viusid, a nutritional supplement, reduce the mortality and the complications (ascites, spontaneous bacterial peritonitis, hepatorenal syndrome, hepatic encephalopathy, gastrointestinal bleeding, sepsis and hepatocellular carcinoma) of patients with cirrhosis of the liver secondary to hcv infection in comparison with placebo, during 96 weeks of treatment.


Eligibility criteria:
inclusion criteria: * histological or clinical diagnosis of cirrhosis. * hcv infection confirmed on a positive test for anti-hcv antibody and hcv rna detectable in serum by polymerase chain reaction. * patients who were non-responders to previous treatment with pegylated interferon and ribavirin or naïve patients with decompensated cirrhosis (child-pugh score ≥ 7) who had contraindicated the antiviral treatment. * presence of compensated or decompensated (stage a, b or c according to the child-pugh classification). * absence of clinical and ultrasonographic evidence of liver cancer, with α-fetoprotein levels ≤ 200 ng/ml. exclusion criteria: * age less than 18 or greater than 70 years. * presence of uncontrollable clinical or biochemical complications related to severe liver failure (hepatic encephalopathy, hepatorenal syndrome, gastrointestinal bleeding, serum bilirubin level greater than 5 mg/dl, international normalized ratio greater than 2.5). * active alcoholism. * serum creatinine greater than 2 mg/dl. * hepatocellular carcinoma. * refusal to participate in the study. * concomitant disease with reduced life expectancy. * severe psychiatric conditions. * co-infection with hepatitis a or b or hiv. * drug dependence. * pregnancy.

Keywords: chronic hepatitis c cirrhosis of the liver mortality complications health-related quality of live hepatocellular carcinoma nutritional supplement
identification and characterization of the methylation abnormalities on whole genome among infertile men

Conditions: Oligospermia

Summary: this study will analyse the sperm global methylation status of 62 infertile men before assisted reproductive techniques. some of these patients (20%) present hypomethylation of h19 locus. a global methylation analysis may reveal others imprinting defects.

an increase of the abnormalities of the imprint was brought back at the child's stemming from assisted reproductive techniques. now abnormalities of methylation could be implied in defects of spermatogenesis and certain abnormalities of development of the male germ cells could be due to modifications abnormal epigenetics. the objective of this research is to determine the frequency of arisen the abnormalities of methylation at the level of the locus h19 in the sperm cells of barren men presenting an unexplained oligozoospermia and to determine if these changes are a reflection of abnormalities of the profiles of methylation of the whole genome. the patients will realize a taking of sperm having signed the consent.

Eligibility criteria:
inclusion criteria: * men from 18 to 45 years old, presenting an idiopathic oligozoospermia lower than 10 million sperm cells / ml and include in a program of medically assisted conception * patients with social security * patients having signed the informed consent exclusion criteria: * infertility with a neoplastic origin: patients subjected to a treatment potentially sterilizing (chemotherapy or radiotherapy). * infertility with an infectious origin * infertility with a traumatic origin * infertility bound to a chromosomal abnormality or a microdeletion of y * histories of cryptorchidism, of varicocele

Keywords: methylation micro array locus h19 male infertility
integrating data, algorithms and clinical reasoning for surgical risk assessment

Conditions: Postoperative Complications

Summary: brief summary: the goal of this study is to implement and test an intelligent perioperative system (ips) that in real-time predicts risk for postoperative complications using routine clinical data collected in electronic health records. the accuracy of computer-generated risk scores will be compared to physician's risk scores for the same patients. physicians will be also asked to provide the opinion regarding the computer-generated risk scores using interactive interface with the program. the information regarding the risk scores performance will be collected during the two 6-month periods. the accuracy of ips and physicians will be compared at the end at those two time periods.

postoperative complications significantly increase morbidity, mortality and cost after surgery. in the current clinical practice the prediction of the risk for developing complications after surgery is manly based on physicians' clinical judgment. the predictive accuracy of that judgment is limited and poorly studied. the investigators will design an intelligent perioperative system (ips) as the set of computer software and algorithms that in real-time predict risk for postoperative complications using routine clinical data in electronic health records. the system is designed as the self-learning system with the ability to interact with physicians and solicit their feedback. this study will compare the clinical judgment of physicians with computer generated risk scores for patients undergoing major surgery. all surgeons and anesthesiologists at large single-center tertiary academic center will be recruited to participate in this study. the ips system will be implemented in real time and will generate risk scores for postoperative complications for patients planned to undergo surgery performed by the physicians enrolled in the study. physicians will be asked to provide their risk scores (using visual analog risk scale from 0-100) for the same patients before and after interacting with the ips. they will also have the opportunity to review computer-generated risk scores and provide their feedback. the information will be collected during two six-month periods. at the end of each 6-months period predicted risk estimates will be compared to the true occurrence of the complications. predictive performance of physicians' risk scores will be compared to ips generated risk scores using the comparison between area under the receiver-operating curve (auc), sensitivity, specificity and positive and negative predicted values.

Eligibility criteria:
inclusion criteria: surgeons and anesthesiologists working in adult inpatient operative practices. exclusion criteria: surgeons and anesthesiologists working in obstetric and pediatric practices.

Keywords: risk assessment sepsis acute kidney injury (aki)
will decreased noradrenergic activity normalize information processing in patients with schizophrenia?

Conditions: Schizophrenia

Summary: the investigators want to try to improve information processing in schizophrenic patients via pharmacological intervention. the hypothesis is that decreased noradrenergic activity will normalize information processing (ppi, p50 gating, p300, and mismatch negativity) in patients with schizophrenia.

a number of reports in literature provide evidence for, among others, an increased central noradrenergic activity in schizophrenia. in addition to this increased noradrenergic activity, patients with schizophrenia often show reduced filtering of sensory information, which is reflected in reduced p50 suppression and reduced prepulse inhibition of the startle reflex (ppi). in two separate initial studies in our laboratory, we found reduced sensory gating following administration of imipramine (a combined noradrenergic and serotonergic agonist) and desipramine (a highly specific noradrenergic agonist) to healthy volunteers. this provides evidence for a direct causal relation between the increased noradrenergic activity and the disturbed gating of sensory information, as both commonly found in patients with schizophrenia. therefore, in a follow-up study, the effects of a noradrenergic antagonist will be investigated on the sensory gating of patients with schizophrenia. to further extend the data of our initial studies, the patients will additionally be tested for two psychophysiological parameters of attention that are usually found to be disturbed in patients with schizophrenia, i.e. mismatch negativity and selective attention. the design will conform to a double blind, placebo controlled experiment, in which either four doses (0.25 ug, 50 ug, 75 ug or 150 ug)of clonidine or placebo will be added to the current medical treatment of 20 male patients with schizophrenia on five occasions, separated by at least a week, after which they are tested in the copenhagen psychophysiological test battery (cptb).in order to test the effects of clonidine in healthy volunteers, 20 healthy males will receive a fixed dose of 0.15 mg clonidine or placebo on two separate occasions separated by at least a week, after which they will be tested in the cptb as well.

Eligibility criteria:
inclusion criteria: * patients: * male subjects * meeting the dsm-iv diagnosis of schizophrenia * controls: * male subjects * good physical and mental health meeting criteria "never mentally ill", which will be evaluated with a medical history checklist * non smokers exclusion criteria: * patients: * a p50 suppression or ppi score falling within a range of 10 percent above or below the mean score of the healthy control group * controls: * current use of any medication * any subject who has received any investigational medication within 30 days prior to the start of this study * history of neurologic illness * history of psychiatric illness in first-degree relatives, evaluated with dsm-iv criteria * history of alcohol and drug abuse.

Keywords: schizophrenia information processing ppi p50 gating p300 mismatch negativity clonidine
study to evaluate the safety, tolerability, and pharmacokinetics of ion464 administered to adults with multiple system atrophy (horizon)

Conditions: Multiple System Atrophy

Summary: the primary objectives are to evaluate the safety and tolerability of multiple doses of ion464 administered via intrathecal (it) injection (part 1) and to evaluate the long-term safety and tolerability of ion464 (part 2) in participants with multiple system atrophy (msa). the secondary objectives are to evaluate the pharmacodynamic (pd) effect of ion464 on the level of a potential biomarker of target engagement (parts 1 and 2) and to evaluate the pharmacokinetic (pk) profile of ion464 in serum (part 1).

this is a first-in-human, randomized, blinded, placebo-controlled, multiple-ascending-dose (mad) study (part 1) to evaluate the safety, tolerability, pk, and pd of ion464 in adult participants diagnosed with msa with a long-term extension (lte) (part 2). the study will include up to approximately 40 participants. part 1 of the study consists of a screening period of up to 6 weeks, a treatment period of 12 weeks, and a follow-up period of 24 weeks. the study duration for each participant in part 2 will be approximately 96 weeks, which consists of a 72-week treatment period and a 24-week follow-up period.

Eligibility criteria:
key inclusion criteria: * screening single-photon emission computed tomography (spect) with datscan™ (ioflupane i123 injection) results demonstrating loss (whether symmetric or asymmetric) of dopamine nerve terminals in the striatum consistent with neurodegenerative parkinsonism, as assessed with qualitative, visual read. * diagnosed with probable or possible msa, either parkinsonian-type (msa-p) or cerebellar-type (msa-c). * must be able to walk unassisted for at least 10 meters (approximately 30 feet) key exclusion criteria: * presence of cognitive dysfunction (defined as montreal cognitive assessment (moca) score \<25) * family history of ataxia or parkinsonism and known genetic cause of ataxia or parkinsonism. note: other protocol defined inclusion/ exclusion criteria may apply.
effects of gynecological age on lh sensitivity to energy availability

Conditions: Anovulation; Amenorrhea; Infertility; Starvation

Summary: the purpose of this experiment is to investigate whether the dependence of luteinizing hormone pulsatility on energy availability declines during adolescence.

the incidence of menstrual disorders declines during adolescence. this has long been attributed to the gradual "maturation" of the hypothalamic-pituitary-ovarian axis, but the mechanism of this "maturation" is not known. ovarian function critically depends on the pulsatile secretion of gonadotropin-releasing hormone (gnrh) by the hypothalamus and on the consequent and more readily assessed pulsatility of luteinizing hormone (lh) secretion by the pituitary. lh pulsatility has been shown to depend on energy availability, operationally defined as dietary energy intake minus exercise energy expenditure. the effects of energy availability on lh pulsatility are thought to be mediated by certain metabolic substrates and hormones. comparison: by manipulating diet and exercise regimens, contrasting energy availability treatments of 10 and 45 kilocalories per kilogram of fat-free mass per day are being administered to adolescents with 5-8 years of gynecological age and to adults with 14-18 years of gynecological age for five days in the early follicular phase of separate menstrual cycles. effects of low energy availability on lh pulsatility and on selected metabolic substrates and hormones are being measured.

Eligibility criteria:
inclusion criteria: * 5-8 or 14-18 years of gynecological age * menstrual cycles of 26 to 32 days for the previous 3 months * luteal phase length \>11 days * 18-32% body fat exclusion criteria: * smoking * oral contraceptives * hematocrit \<35% * diet with \ 55 kcal/kgffm/day of energy * habitually performing more than 60 minutes/week of aerobic exercise * histories or evidence of heart, liver, or kidney disease, diabetes, menstrual or thyroid disorders, pregnancy, lactation, and congenital or acquired orthopedic abnormalities

Keywords: lh pulsatility energy availability exercise diet gynecological age
study to evaluate treating chronic cerebrospinal venous insufficiency (ccsvi) in multiple sclerosis patients

Conditions: Multiple Sclerosis

Summary: this is a single center, multispecialty, randomized double blind placebo control feasibility clinical trial. the purpose is to evaluate the safety, feasibility and efficacy of percutaneous transluminal angioplasty in treating extracranial venous obstructive lesions, and its influence on the clinical outcomes of multiple sclerosis (ms) patients that have been found to have chronic cerebrospinal venous insufficiency (ccsvi).


Eligibility criteria:
inclusion criteria: * must be 18 years old or greater and less than or equal to 65 years of age * score of 0 to 7 on the edss scale * diagnosis of relapsing remitting or secondary progressive multiple sclerosis by a neurologist and confirmed by one of the independent study neurologists * presence of greater than or equal to 50 percent stenosis of the extracranial veins as determined by venogram * informed consent signed by patient exclusion criteria: * patient is unwilling to comply with the follow up * patient is pregnant * diagnosis of primary progressive ms by a certified neurologist confirmed by one of the study neurologists * presence of less than 50 percent stenosis of the extracranial veins as determined by venogram * presence of other medical illnesses or a psychiatric condition that in the opinion of the investigator may cause the subject to be non-compliant with the protocol requirements * life expectancy is less than one year * lack of mental capacity to consent * creatinine level of greater than 2.5 or is dialysis dependant * enrollment in another clinical study

Keywords: chronic cerebrospinal venous insufficiency
verapamil for neuroprotection in stroke

Conditions: Ischemic Stroke

Summary: the purpose of this research study is to test an experimental procedure called intra-arterial delivery of verapamil in patients diagnosed with acute ischemic stroke. this study investigates the safety of intra-arterial delivery of verapamil, a drug used to treat vasospasm (spasm of a blood vessel), and how it affects recovery from stroke. recruitment is limited to patients that have received mechanical thrombectomy as standard of care.


Eligibility criteria:
inclusion criteria: * written informed consent * 18 years of age and over * acute onset focal neurologic deficit consistent with acute ischemic stroke, or computed tomographic scan consistent with acute cerebral ischemia * candidate for mechanical thrombectomy procedure * onset of symptoms less than 8 hours * measurable neurologic deficit (nihss ≥4) * willingness to follow up with rehabilitation therapy * anticipated life expectancy of at least 3 months exclusion criteria: * pregnancy or suspected pregnancy (pregnancy test will be done on women of child-bearing potential) * hepatic and/or renal insufficiency (lft's\>3× upper limit of normal; crcl \< 30ml/min) * thrombocytopenia (platelet count \<75,000/mm3) * history of intolerance to verapamil * previous functional disability (modified rankin \> 1) * severe stroke (nihss\>22) * stuporous or comatose * unlikely to be available for 90 day follow-up
soluble advanced glycation end product (srage) levels

Conditions: Obese Patients

Summary: the aim of this study is to evaluate srage levels in children with obesity and to determine the relationship between metabolic status and srage levels in childhood obesity


Eligibility criteria:
inclusion criteria: clinical diagnosis of obesity bmi over 95th percentile bmi z-score over 2 exclusion criteria: primary hyperlipidemia primary liver disease hypothyroidism diabetes

Keywords: children, obesity, srage